Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bevacizumab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Patient Access to Affordable Cancer Treatment Increases with the Launch of New Biosimilar in Canada
Details : The company, a pioneer and leader in oncology biosimilars in Canada, launched Bambevi® (bevacizumab), which is used in combination with chemotherapy to treat specific types of colorectal, lung, brain and ovarian cancer.
Product Name : Bambevi
Product Type : Antibody
Upfront Cash : Inapplicable
September 11, 2021
Lead Product(s) : Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable